BostonGene to present 6 posters at AACR

By The Science Advisory Board staff writers
April 11, 2022

BostonGene will present six poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 8-13 in New Orleans. The presentations will highlight BostonGene’s advancement of novel analytical tools and technologies developed to enhance detection and diagnosis in cancer patients.

The following three presentations are scheduled for April 11 from 9 a.m. to 12:30 p.m.

Poster 1216 "Combinatory technologies for single sample gene expression projection onto a cohort sequenced with a different technology for personalized clinical decision-making"
Poster 1227 "Molecular-based tumor grade predictor for breast cancer, clear cell renal cell carcinoma, and lung adenocarcinoma"
Poster 2061 "Deep immune profiling by mass cytometry revealed an association between the state of immune system before treatment and response to checkpoint inhibitor therapy in clear cell renal cell carcinoma"

The remaining three posters will be presented as e-posters. BostonGene will exhibit at booth #3641.

If you like this content, please share it with a colleague!

Related Reading

BostonGene, WellDyne announce strategic partnership
BostonGene Corporation and WellDyne have formed a strategic partnership to improve therapeutic decision-making for cancer patients. Using BostonGene's...

BostonGene touts prostate cancer research results
Biomedical software firm BostonGene is highlighting research published in Clinical Cancer Research that identified particular molecular, cellular,...